JPMorgan Chase & Co. cut its position in Axsome Therapeutics Inc. (NASDAQ:AXSM) by 0.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,582,231 shares of the company’s stock after selling 4,425 shares during the period. JPMorgan Chase & Co. owned approximately 8.26% of Axsome Therapeutics worth $11,930,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC bought a new stake in shares of Axsome Therapeutics during the first quarter valued at $296,000. Bank of New York Mellon Corp bought a new stake in shares of Axsome Therapeutics during the second quarter valued at $161,000. Finally, California State Teachers Retirement System bought a new stake in shares of Axsome Therapeutics during the second quarter valued at $176,000. Hedge funds and other institutional investors own 30.30% of the company’s stock.
Axsome Therapeutics Inc. (NASDAQ:AXSM) traded up 4.82% on Monday, reaching $8.26. The company’s stock had a trading volume of 51,549 shares. The firm has a 50-day moving average of $7.44 and a 200-day moving average of $8.44. The company’s market capitalization is $158.17 million. Axsome Therapeutics Inc. has a one year low of $5.37 and a one year high of $15.74.
AXSM has been the subject of several analyst reports. Zacks Investment Research cut Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. Brean Capital restated a “buy” rating on shares of Axsome Therapeutics in a report on Wednesday, August 10th. Finally, Cantor Fitzgerald set a $13.00 price target on Axsome Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 10th.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.